Journal of Chinese Pharmaceutical Sciences ›› 2022, Vol. 31 ›› Issue (5): 334-342.DOI: 10.5246/jcps.2022.05.029
• Short review • Previous Articles Next Articles
Haiyan Wu1, Xiang Zhang1, Shanshan Ding1, Guohua Zhang1, Linlin Tang3, Lin Tang2,*()
Received:
2021-09-24
Revised:
2021-10-29
Accepted:
2021-12-29
Online:
2022-06-02
Published:
2022-06-02
Contact:
Lin Tang
Supporting:
Haiyan Wu, Xiang Zhang, Shanshan Ding, Guohua Zhang, Linlin Tang, Lin Tang. Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 334-342.
[1] |
Ni, X. Dignosis and treatment guideline of community acquired pneumonia in children. Clin. Educ. Gen. Pract. 2019, 09, 771–777.
|
[2] |
Chen, Z.M.; Shang, Y.X.; Zhao, S.Y.; Xin, D.L.; Xu, B.P.; Zeng, Y.J.; Lu, M. Zhang, H.L.; Bao, J. Expert consensus on diagnosis and treatment of mycoplasma pneumoniae pneumonia in children. J. Appl. Clin. Pediatr. 2015, 17, 1304–1308.
|
[3] |
Cao, B.; Qu, J.X.; Yin, Y.D.; Eldere, J.V. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin. Respir. J. 2017, 11, 419–429.
|
[4] |
Yamazaki, T.; Kenri, T. Epidemiology of mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front. Microbiol. 2016, 7, 693.
|
[5] |
Gong, C.H.; Liu, F. Mycoplasma pneumoniae pneumonia in children: a clinical analysis of 293 cases. J. Tongji Univ (Med. Sci.). 2020, 41, 331–337.
|
[6] |
Han, X.H. Treatment of refractory mycoplasma pneumoniae pneumonia in children. Med. Philos. B. 2018, 39, 12–15.
|
[7] |
Liu, X.M.; Jing, S.J. Research progress on risk factors related to refractory Mycoplasma pneumoniae pneumonia. China Mod. Med. 2020, 03, 12–16.
|
[8] |
Zhang, W.C.; Zhao, M.C.; Feng, Z.S.; Li, M.; Guo, Y.H.; Li, G.X. The clinical value of pellet agglutination assay for MP antibody titer and colloidal gold method for simultaneously detection of MP-IgM and MP-IgG in children with mycoplasma pneumonia. J. Hebei Med. Univ. 2018, 39, 1058–1061, 1066.
|
[9] |
Wang, H.; Zhao, S.Y. Research progress in pathogenesis, diagnosis and treatment of mycoplasma pneumoniae pneumonia in children. World Clin. Drugs. 2020, 5, 390–398.
|
[10] |
Li, S.L.; Sun, H.M. Progress in global drug resistance patterns and drug resistance mechanisms of mycoplasma pneumoniae. Chin. J. Microbiol. Immunol. 2018, 5, 5395–5400.
|
[11] |
Cao, B.; Zhao, C.J.; Yin, Y.D.; Zhao, F.; Song, S.F.; Bai, L.; Zhang, J.Z.; Liu, Y.M.; Zhang, Y.Y.; Wang, H.; Wang, C. High prevalence of macrolide resistance in mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin. Infect. Dis. 2010, 51, 189–194.
|
[12] |
Waites, K.B. What’s new in diagnostic testing and treatment approaches for Mycoplasma pneumoniae infections in children? Adv. Exp. Med. Biol. 2011, 719, 47–57.
|
[13] |
Atkinson, T.P.; Waites, K.B. Mycoplasma pneumoniae infections in childhood. Pediatr. Infect. Dis. J. 2014, 33, 92–94.
|
[14] |
Zhou, P.X.; Zhou, W.; Wang, X.L.; Zhang, X.L.; Xu, B.P.; Tong, X.M.; Shen, K.L.; Zhai, S.D. Expert consensus on rapid advice guideline for intravenous azithromycin in children. Clin. Med. J. 2019, 17, 39–45.
|
[15] |
Tang, J.Y.; Wang, Q.; Wu, S.J.; Xu, H.P.; Zhang, S.H.; Zhang, G. Efficacy and safety of different-course intravenous azithromycin treatments for mycoplasma pneumonia in children Meta-analysis. China Pharmacist. 2020, 1, 97–100.
|
[16] |
Zheng, Y.; Liu, S.P.; Xu, B.P.; Shi, Z.R.; Wang, K.; Yang, J.B.; Huang, X.; Tang, B.H.; Chen, X.K.; Shi, H.Y.; Zhou, Y.; Wu, Y.E.; Qi, H.; Jacqz-Aigrain, E.; Shen, A.D.; Zhao, W. Population pharmacokinetics and dosing optimization of azithromycin in children with community-acquired pneumonia. Antimicrob. Agents Chemother. 2018, 62, 9.
|
[17] |
Lin, J.T.; Zhang, Y.M.; Wang, C.Z.; Zhou, X.; Huang, M.; Liu, C.T.; Wu, C.G.; Wan, H.Y.; Yu, W.C.; Dai, Y.R. Antibacterial external action of macrolides and expert consensus on clinical application. Chin. J. Internal. Med. 2017, 7, 546–557.
|
[18] |
DiNicolantonio, J.J. Azithromycin for prevention of exacerbations of COPD. N Engl J. Med. 2011, 365, 2235.
|
[19] |
He, W.C.; Zhang, X.J.; Wang, S. Clinical analysis of the combination of modified Huanglian Jiedu Decoction and erythromycin in the treatment of refractory mycoplasma pneumonia. Jilin Med. J. 2020, 12, 2955–2957.
|
[20] |
He, W.C.; Zhang, X.J.; Zhang, W.J. Observation on the therapeutic effect of Qingrejiedu Decoction combined with erythromycin on refractory mycoplasma pneumonia in children. Mod. J. Integr. Tradit. Chin. West. Med. 2020, 20, 2198–2202.
|
[21] |
Liang, Y.T.; Li, L.; Xu, G.M. Clinical effect analysis of low dose methylprednisolone sodium succinate combined with erythromycin in the treatment of children with refractory mycoplasma pneumonia. J. North Pharm. 2020, 07, 92–93.
|
[22] |
Dai, X.Q. Evaluation of Glucocorticoid-assisted Injection of Erythromycin Lactate in the Treatment of Refractory Mycoplasma Pneumoniae Pneumonia in Children. World Latest Med. Inf. 2019, A3, 42–43.
|
[23] |
Han, X.; Miao, N.Y.; Wen, H.M.; Wang, C.H. Minocycline in children with macrolide-resistant mycoplasma pneumoniae pneumonia. J. Pediatr. Pharm. 2016, 22, 17–19.
|
[24] |
Wang, Y.X.; Chu, D.M.; Yao, L.; Wang, B.L. Therapeutic effect of minocycline combined with methylprednisolone sodium succinate in the treatment of refractory mycoplasma pneumoniae pneumonia. Shandong Med. J. 2013, 44, 52–53.
|
[25] |
Chen, Z.M.; Zhao, Y.S.; Wang, Y.S.; Lu, Q.; Zheng, Y.J.; Liu, Y.; Lu, J.R.; Yang, D.H. Some problems of mycoplasma pneumoniae infection. Chin. J. Pediatr. 2016, 02, 84–87.
|
[26] |
Korean Centers for Disease Control and Prevention, Korean National Institute of Health. Korean Antimicrobial Resistance Monitoring System annual report. Chungbuk: The Centers. 2011.
|
[27] |
Chen, Y.; Xue, F.; Zhang, Y.F. Clinical observation of minocycline adjuvant therapy for refractory mycoplasma pneumoniae pneumonia. J. Clin. Pediatr. 2012, 8, 795.
|
[28] |
Infectious Diseases Committee of China Medical Education Association. Expert consensus on clinical application of antimicrobial pharmacokinetic/pharmacodynamics theory. Chin. J. Union Respiration. 2018, 6, 409–446.
|
[29] |
Product Information: MINOCIN(R) oral suspension, minocycline hcl oral suspension. Triax Pharmaceuticals, LLC, Cranford, NJ. 2010.
|
[30] |
Product Information: minocycline HCl oral tablets, minocycline HCl oral tablets. Par Pharmaceutical Companies, Inc. (per Manufacturer), Spring Valley, NY. 2011.
|
[31] |
Product Information: MINOCIN(R) pellet-filled oral capsules, minocycline hcl pellet-filled oral capsules. Triax Pharmaceuticals, LLC, Cranfrod, NJ. 2010.
|
[32] |
Yang, X.; Qin, X.G.; Xin, D.L. The clinical analysis of the minocycline hydrochloride treatment for children with mycoplasmal pneumonia. Chin. Med. Rec. 2013, 14, 64–66.
|
[33] |
Duan, L.F.; Zhou, J. Medication consultation on minocycline administration in a 4-year-old with refractory Mycoplasma pneumoniae and literature review. Cent. South Pharm. 2020, 11, 1928–1931.
|
[34] |
Zeng, N.; Wang, X.J.; Sun, H.J. Safety analysis of minocycline in the treatment of refractory mycoplasma pneumoniae pneumonia in children. Pharm. Care Res. 2020, 20, 137–139.
|
[35] |
Okada, T.; Morozumi, M.; Tajima, T.; Hasegawa, M.; Sakata, H.; Ohnari, S.; Chiba, N.; Iwata, S.; Ubukata, K. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin. Infect. Dis. 2012, 55, 1642–1649.
|
[36] |
Yang, H.J. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J. Pediatr. 2019, 62, 199–205.
|
[37] |
Zeng, N.; Wang, X.J.; Sun, H.J. Safety analysis of minocycline in the treatment of refractory Mycoplasma pneumoniae pneumonia in children. Pharm. Care Res. 2020, 20, 137–139.
|
[38] |
Wu, J.Y.; Sun, S.M. Expert consensus on the use of fluoroquinolones in children. Pharm. Today. 2018, 01, 1–10.
|
[39] |
Guiding Principles of Clinical Application of Antibacterial Agents (2015 Edition), Beijing: People’s Health Publishing House. 2015, 57.
|
[40] |
Jiang, Z.F.; Shen, K.L.; Shen, Y.; Zhu, F.T. Practical Pediatrics. 8th Edition. Beijing: People’s Medical Publishing House. 2015.
|
[41] |
Averbuch, D.; Hidalgo-Grass, C.; Moses, A.E.; Engelhard, D.; Nir-Paz, R. Macrolide resistance in mycoplasma pneumoniae, Israel, 2010. Emerg. Infect. Dis. 2011, 17, 1079–1082.
|
[42] |
Cardinale, F.; Chironna, M.; Dumke, R.; Binetti, A.; Daleno, C.; Sallustio, A.; Valzano, A.; Esposito, S. Macrolide-resistant mycoplasma pneumoniae in paediatric pneumonia. Eur. Respir. J. 2011, 37, 1522–1524.
|
[43] |
Lin, M.; Shi, L.; Huang, A.; Liang, D.; Ge, L.; Jin, Y. Efficacy of levofloxacin on macrolide-unresponsive and corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children. Ann. Palliat. Med. 2019, 8, 632–639.
|
[44] |
Dai, F.F.; Liu, F.Q.; Chen, X.; Yang, J.; Wang, K.; Guo, C.Y. The treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. J. Clin. Pharm. Ther. 2021, 46, 705–710.
|
[45] |
Liang, S.J. Clinical effect analysis of quinolones in the treatment of children with refractory mycoplasma pneumoniae pneumonia and its effect on immune function. Shenyang: China Med. Univ. 2020.
|
[46] |
Liu, L.M.; Yuan, Y.H.; Xie, M.Y.; Gu, R.; Zhao, X.D. Musculoskeletal adverse drug events of levaquin in children: a systematic review. Chin. J. Evid. Based Pediatr. 2015, 10, 193–197.
|
[47] |
Bradley, J.S.; Kauffman, R.E.; Balis, D.A.; Duffy, C.M.; Gerbino, P.G.; Maldonado, S.D.; Noel, G.J. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014, 134, e146–e153.
|
[48] |
Patel, K.; Goldman, J.L. Safety concerns surrounding quinolone use in children. J. Clin. Pharmacol. 2016, 56, 1060–1075.
|
[1] | Min Wan, Jinyu Liu, Guangyi Yu, Suiju Tong, Lei Ke, Yu Zhang, Ruxu You. Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 417-425. |
[2] | Yingyan Yan, Peizhi Mao, Yi Chen, Longhui Shen. Analysis of alternation with ibuprofen and acetaminophen in outpatient and emergency departments of a children’s hospital [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 369-373. |
[3] | School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Prof. Xianrong Qi have provided a new delivery strategy for accurate diagnosis and treatment of glioma [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(6): 441-442. |
[4] | Shurong Shao, Wei Guo. Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(1): 56-61. |
[5] | http://www.fda.gov. Information from US FDA [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(10): 724-731. |
[6] | Daiying Zhou, Li Ding, Xi Wang, Juan Ma, Wolin Huang, Susan Goodin, Xi Zheng. Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(11): 827-833. |
[7] | Mohammad Asif. Newly developed drugs invented to treat tuberculosis in clinical trial [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(1): 1-22. |
[8] | Xiaohui Xie, Fei Wang, Jiayu Cui. The impact of obesity in managing diabetes [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(6): 412-418. |
[9] | Lingli Mu, Sanwang Li, Rui Zhou, Fang Tang, Peng Yu. The application of immunoassay in bioanalysis [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(4): 205-216. |
[10] | Fei Peng, Pengchao Gao, Xiangtao Wang, Xin Hu*. Acid sensitive doxorubicin-PAMAM with tumor targeting profile [J]. , 2013, 22(1): 81-88. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||